Scientific Background

Please see the published, peer-reviewed article, Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. CNS Drugs 2014 August, 28(8):679-697.

PSE.SR.screenshot  PSE.SR.p3

 Scientific References from the article:

1.Mendis S. Stroke disability and rehabilitation of stroke: World Health Organization perspective. Int J Stroke. 2013;8(1):3-4.

2.Skolarus LE, Burke JF, Brown DL, Freedman VA. Understanding stroke survivorship: expanding the concept of poststroke disability. Stroke. 2014;45(1):224-30.

3.Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, et al. Stroke: working toward a prioritized world agenda. Stroke. 2010;41(6):1084-99.

4.Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145-55.

5.Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, Depuy V. Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury: An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept. CNS Drugs. 2012;26(12):1051-70.

6.Banks WA, Plotkin SR, Kastin AJ. Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation. 1995;2(3):161-5.

7.Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature medicine. 2000;6(8):916-9.

8.Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466-8.

9.Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, et al. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer’s disease. Neuroscience letters. 2009;449(3):240-5.

10.Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6):985-1002.

11.Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Immediate neurological recovery following perispinal etanercept years after brain injury. Clinical drug investigation. 2014;34(5):361-6.

12.Batson OV. The Function of the Vertebral Veins and Their Role in the Spread of Metastases. Ann Surg. 1940;112(1):138-49.

13.LaBan MM, Chamberlain CC, Jaiyesimi I, Shetty AN, Wang AM. Paravertebral muscle metastases as imaged by magnetic resonance venography: a brief report. American journal of physical medicine & rehabilitation / Association of Academic Physiatrists. 1998;77(6):553-6.

14.Anderson R. Diodrast studies of the vertebral and cranial venous systems to show their probable role in cerebral metastases. Journal of neurosurgery. 1951;8(4):411-22.

15.Batson OV. The vertebral vein system. Caldwell lecture, 1956. Am J Roentgenol Radium Ther Nucl Med. 1957;78(2):195-212.

16.Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed. 2006;8(1):53.

17.Tubbs RS, Hansasuta A, Loukas M, Louis RG, Jr., Shoja MM, Salter EG, et al. The basilar venous plexus. Clinical anatomy. 2007;20(7):755-9.

18.Nathoo N, Caris EC, Wiener JA, Mendel E. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery. 2011;69(5):1007-14; discussion 14.

19.Pearce JM. The craniospinal venous system. Eur Neurol. 2006;56(2):136-8.

20.Etz CD, Luehr M, Kari FA, Bodian CA, Smego D, Plestis KA, et al. Paraplegia after extensive thoracic and thoracoabdominal aortic aneurysm repair: does critical spinal cord ischemia occur postoperatively? The Journal of thoracic and cardiovascular surgery. 2008;135(2):324-30.

21.De Wyngaert R, Casteels I, Demaerel P. Orbital and anterior visual pathway infection and inflammation. Neuroradiology. 2009;51(6):385-96.

22.Gasco J, Kew Y, Livingston A, Rose J, Zhang YJ. Dissemination of prostate adenocarcinoma to the skull base mimicking giant trigeminal schwannoma: anatomic relevance of the extradural neural axis component. Skull base : official journal of North American Skull Base Society  [et al]. 2009;19(6):425-30.

23.Morimoto A, Takase I, Shimizu Y, Nishi K. Assessment of cervical venous blood flow and the craniocervical venus valve using ultrasound sonography. Legal medicine. 2009;11(1):10-7.

24.Dumont TM, Stockwell DW, Horgan MA. Venous air embolism: an unusual complication of atlantoaxial arthrodesis: case report. Spine. 2010;35(22):E1238-40.

25.Dabus G, Batjer HH, Hurley MC, Nimmagadda A, Russell EJ. Endovascular treatment of a bilateral dural carotid-cavernous fistula using an unusual unilateral approach through the basilar plexus. World Neurosurg. 2012;77(1):201 e5-8.

26.Hojlund J, Sandmand M, Sonne M, Mantoni T, Jorgensen HL, Belhage B, et al. Effect of head rotation on cerebral blood velocity in the prone position. Anesthesiology research and practice. 2012;2012:647258.

27.Blaylock RL. Immunology primer for neurosurgeons and neurologists part 2: Innate brain immunity. Surg Neurol Int. 2013;4:118.

28.Puri AS, Telischak NA, Vissapragada R, Thomas AJ. Analysis of venous drainage in three patients with extradural spinal arteriovenous fistulae at the craniovertebral junction with potentially benign implication. J Neurointerv Surg. 2013.

29.Strong C, Yanamadala V, Khanna A, Walcott BP, Nahed BV, Borges LF, et al. Surgical treatment options and management strategies of metastatic renal cell carcinoma to the lumbar spinal nerve roots. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2013;20(11):1546-9.

30.Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous drainage of the spine and spinal cord: A comprehensive review of its history, embryology, anatomy, physiology, and pathology. Clinical anatomy. 2014.

31.Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28.

32.Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128(3):519-48.

33.Clark I. New hope for survivors of stroke and traumatic brain injury. CNS Drugs. 2012;26(12):1071-2.

34.Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer’s disease links numerous treatment rationales. Pharmacol Rev. 2012;64(4):1004-26.

35.Tobinick E. Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(1):99-109.

36.Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965;58:295-300.

37.Miklossy J. Alzheimer’s disease – a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria. Journal of neuroinflammation. 2011;8:90.

38.See A. Use of Human Epidemiology Studies in Proving Causation. Defense Counsel Journal. 2000;67:478-87.

39.Kaplan BJ, Giesbrecht G, Shannon S, McLeod K. Evaluating treatments in health care: the instability of a one-legged stool. BMC Med Res Methodol. 2011;11:65.

40.Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke with intravenous TNFalpha decoy receptor-Trojan horse fusion protein. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2012;32(10):1933-8.

41.King MD, Alleyne CH, Jr., Dhandapani KM. TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. Neuroscience letters. 2013;542:92-6.

42.Lei B, Dawson HN, Roulhac-Wilson B, Wang H, Laskowitz DT, James ML. Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage. Journal of neuroinflammation. 2013;10(1):103.

43.Works MG, Koenig JB, Sapolsky RM. Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2013.

44.Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115(4):921-9.

45.Esposito E, Cuzzocrea S. Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci. 2011;32(2):107-15.

46.Wade DT, Wood VA, Heller A, Maggs J, Langton Hewer R. Walking after stroke. Measurement and recovery over the first 3 months. Scand J Rehabil Med. 1987;19(1):25-30.

47.Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Recovery of walking function in stroke patients: the Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995;76(1):27-32.

48.Friedman PJ. Gait recovery after hemiplegic stroke. Int Disabil Stud. 1990;12(3):119-22.

49.Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. Journal of neuroinflammation. 2008;5:3.

50.Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Immediate neurological recovery following perispinal etanercept years after brain injury. Clinical Drug Investigation. 2014(epub March 20, 2014 doi: 10.1007/s40261-014-0186-1).

51.Clark IA, Chaudhri G, Cowden WB. Roles of tumour necrosis factor in the illness and pathology of malaria. Trans R Soc Trop Med Hyg. 1989;83(4):436-40.

52.Goodman JC, Robertson CS, Grossman RG, Narayan RK. Elevation of tumor necrosis factor in head injury. J Neuroimmunol. 1990;30(2-3):213-7.

53.Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer’s disease. Neurobiol Aging. 2001;22(6):873-83.

54.Sjogren M, Folkesson S, Blennow K, Tarkowski E. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry. 2004;75(8):1107-11.

55.Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res. 2007;4(4):378-85.

56.John CC, Panoskaltsis-Mortari A, Opoka RO, Park GS, Orchard PJ, Jurek AM, et al. Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. Am J Trop Med Hyg. 2008;78(2):198-205.

57.Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M. Tumor necrosis factor-{alpha} triggers a cytokine cascade yielding postoperative cognitive decline. Proceedings of the National Academy of Sciences of the United States of America. 2010.

58.Butterworth RF. Neuroinflammation in acute liver failure: mechanisms and novel therapeutic targets. Neurochemistry international. 2011;59(6):830-6.

59.Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. CNS Neurol Disord Drug Targets. 2011;10(3):391-403.

60.Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio CC. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF- alpha contents and by stimulating newly formed neurogenesis. Mediators Inflamm. 2013;2013:620837.

61.Chio CC, Chang CH, Wang CC, Cheong CU, Chao CM, Cheng BC, et al. Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-alpha. BMC Neurosci. 2013;14(1):33.

62.Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013;84(9):956-62.

63.Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-79.

64.Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, et al. Effects of Etanercept and Minocycline in a rat model of spinal cord injury. European journal of pain. 2009;13(7):673-81.

65.Chio CC, Lin JW, Chang MW, Wang CC, Yang CZ, Chang CP. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115(4):921-9.

66.Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, et al. Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg. 2011;112(2):454-9.

67.Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PloS one. 2012;7(7):e40065.

68.Butterworth RF. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol. 2013;10(9):522-8.

69.Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today. 2009;14(3-4):168-77.

70.Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs. 2009;23(9):713-25.

71.Breschet G. Essai sur les veines du rachis [ Theses presentees et soutenues publiq. devant les juges concours le 28. Avril 1819]. Paris: Faculte de Medecine de Paris; 1819.

72.Breschet G. Recherches anatomiques physiologiques et pathologiques sur le systáeme veineux. Paris,: Rouen fráeres; 1829. 48 p. p.

73.Gray H, Holmes T. Anatomy, descriptive and surgical. 4th ed. London: Longmans, Green, and co.; 1866.

74.Quain J. The elements of anatomy, seventh edition. Seventh ed. London: James Walton; 1867.

75.Herlihy WF. Revision of the venous system; the role of the vertebral veins. Med J Aust. 1947;1(22):661-72.

76.Netter FH, Ciba Pharmaceutical Products inc., CIBA-GEIGY Corporation. The Ciba collection of medical illustrations : a compilation of pathological and anatomical paintings. Summit, N.J.,: Ciba Pharmaceutical Products; 1958.

77.Groen RJ, Groenewegen HJ, van Alphen HA, Hoogland PV. Morphology of the human internal vertebral venous plexus: a cadaver study after intravenous Araldite CY 221 injection. Anat Rec. 1997;249(2):285-94.

78.LaBan MM, Wilkins JC, Szappanyos B, Shetty AN, Wang AM. Paravertebral plexus of veins (Batson’s)–potential route of paraspinal muscle metastases as imaged by magnetic venous angiography. A commentary. American journal of physical medicine & rehabilitation / Association of Academic Physiatrists. 1997;76(6):517-9.

79.Groen RJ, du Toit DF, Phillips FM, Hoogland PV, Kuizenga K, Coppes MH, et al. Anatomical and pathological considerations in percutaneous vertebroplasty and kyphoplasty: a reappraisal of the vertebral venous system. Spine. 2004;29(13):1465-71.

80.Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous Drainage of the Spine and Spinal Cord: A Comprehensive Review of its History, Embryology, Anatomy, Physiology, and Pathology. Clinical anatomy. 2014;epub.

81.Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev. 1994;6(4):341-60.

82.Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke. 1997;28(6):1233-44.

83.Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res. 1997;778(2):265-71.

84.Zaremba J. Contribution of tumor necrosis factor alpha to the pathogenesis of stroke. Folia Morphol (Warsz). 2000;59(3):137-43.

85.Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand. 2001;104(5):288-95.

86.Zaremba J, Skrobanski P, Losy J. Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed Pharmacother. 2001;55(5):258-63.

87.Kaushal V, Schlichter LC. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci. 2008;28(9):2221-30.

88.Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014.

89.Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, et al. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke. 1994;25(7):1481-8.

90.Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev. 1996;20(3):445-52.

91.Kooijman E, Nijboer CH, van Velthoven CT, Mol W, Dijkhuizen RM, Kesecioglu J, et al. Long-term functional consequences and ongoing cerebral inflammation after subarachnoid hemorrhage in the rat. PLoS One. 2014;9(3):e90584.

92.Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res. 2005;27(3):268-79.

93.Mayne M, Ni W, Yan HJ, Xue M, Johnston JB, Del Bigio MR, et al. Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. Stroke; a journal of cerebral circulation. 2001;32(1):240-8.

94.Xi G, Hua Y, Keep RF, Younger JG, Hoff JT. Systemic complement depletion diminishes perihematomal brain edema in rats. Stroke. 2001;32(1):162-7.

95.Lu A, Tang Y, Ran R, Ardizzone TL, Wagner KR, Sharp FR. Brain genomics of intracerebral hemorrhage. J Cereb Blood Flow Metab. 2006;26(2):230-52.

96.Wagner KR, Beiler S, Beiler C, Kirkman J, Casey K, Robinson T, et al. Delayed profound local brain hypothermia markedly reduces interleukin-1beta gene expression and vasogenic edema development in a porcine model of intracerebral hemorrhage. Acta Neurochir Suppl. 2006;96:177-82.

97.Wasserman JK, Zhu X, Schlichter LC. Evolution of the inflammatory response in the brain following intracerebral hemorrhage and effects of delayed minocycline treatment. Brain Res. 2007.

98.Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke. Stroke. 1996;27(9):1553-7.

99.Castillo J, Davalos A, Alvarez-Sabin J, Pumar JM, Leira R, Silva Y, et al. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology. 2002;58(4):624-9.

100.Dziedzic T, Bartus S, Klimkowicz A, Motyl M, Slowik A, Szczudlik A. Intracerebral hemorrhage triggers interleukin-6 and interleukin-10 release in blood. Stroke. 2002;33(9):2334-5.

101.Woiciechowsky C, Schoning B, Cobanov J, Lanksch WR, Volk HD, Docke WD. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma. 2002;52(2):339-45.

102.Fang HY, Ko WJ, Lin CY. Inducible heat shock protein 70, interleukin-18, and tumor necrosis factor alpha correlate with outcomes in spontaneous intracerebral hemorrhage. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2007;14(5):435-41.

103.Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery. 2006;58(3):542-50; discussion -50.

104.Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305-8.

105.Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487-501.

106.Gururaja TL, Yung S, Ding R, Huang J, Zhou X, McLaughlin J, et al. A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1. Chemistry & biology. 2007;14(10):1105-18.

107.Galustian C, Labarthe M-C, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther. 2004;4(12):1963-70.

108.De Sanctis JB, Mijares M, Suarez A, Compagnone R, Garmendia J, Moreno D, et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov. 2010;4(2):144-8.

109.Zhu X, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri DK, et al. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem. 2003;46(24):5222-9.

110.Baratz R, Tweedie D, Rubovitch V, Luo W, Yoon JS, Hoffer BJ, et al. Tumor necrosis factor-alpha synthesis inhibitor, 3,6′-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem. 2011;118(6):1032-42.

111.Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675-80.

112.Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, et al. IMiD immuno-modulatory compounds block C/EBP{beta} translation through eIF4E down- regulation resulting in inhibition of MM. Blood. 2011;117(19):5157-65.

113.Yoon JS, Lee JH, Tweedie D, Mughal MR, Chigurupati S, Greig NH, et al. 3,6′-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation. J Neurosci Res. 2013;91(5):671-80.

114.Mayhan WG. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood–brain barrier. Brain research. 2002;927(2):144-52.

115.Pan W, Kastin AJ. Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol. 2007;83(6):363-74.

116.Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29(5):1020-30.

117.Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12(4):441-5.

118.Takata F, Dohgu S, Matsumoto J, Takahashi H, Machida T, Wakigawa T, et al. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-?, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflammation. 2011;8(106):1-12.

119.Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16(1):3-11.

120.Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008;135(7):1161-3.

121.Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 2008;135(7):1311-23.

122.Kitanaka C, Kuchino Y. Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ. 1999;6(6):508-15.

123.Laird MD, Wakade C, Alleyne CH, Jr., Dhandapani KM. Hemin-induced necroptosis involves glutathione depletion in mouse astrocytes. Free Radic Biol Med. 2008;45(8):1103-14.

124.Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 1998;8(3):297-303.

125.Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O, Teng X, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nature chemical biology. 2008;4(5):313-21.

126.Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nature chemical biology. 2005;1(2):112-9.

127.King MD, Whitaker-Lea, W.A., Campbell, J., Alleyne, C.H., Dhandapani, K.M. Necrostatin-1 reduces neurovascular injury after intracerebral hemorrhage. Intl J Cell Biol. 2014;In press.

128.Xu X, Chua KW, Chua CC, Liu CF, Hamdy RC, Chua BH. Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury. Brain research. 2010;1355:189-94.

129.You Z, Savitz SI, Yang J, Degterev A, Yuan J, Cuny GD, et al. Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2008;28(9):1564-73.

130.Knoblach SM, Fan L, Faden AI. Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol. 1999;95(1-2):115-25.

131.Low PC, Manzanero S, Mohannak N, Narayana VK, Nguyen TH, Kvaskoff D, et al. PI3Kdelta inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model. Nat Commun. 2014;5:3450.

132.Dubois A, Benavides J, Peny B, Duverger D, Fage D, Gotti B, et al. Imaging of primary and remote ischaemic and excitotoxic brain lesions. An autoradiographic study of peripheral type benzodiazepine binding sites in the rat and cat. Brain Res. 1988;445(1):77-90.

133.Myers R, Manjil LG, Frackowiak RS, Cremer JE. [3H]PK 11195 and the localisation of secondary thalamic lesions following focal ischaemia in rat motor cortex. Neuroscience letters. 1991;133(1):20-4.

134.Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota A, et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology. 2000;55(7):1052-4.

135.Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C, Griffin WS, et al. Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int. 2004;146(2-3):97-104.

136.Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage. 2005;24(2):591-5.

137.Price CJ, Wang D, Menon DK, Guadagno JV, Cleij M, Fryer T, et al. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke. 2006;37(7):1749-53.

138.Folkersma H, Boellaard R, Yaqub M, Kloet RW, Windhorst AD, Lammertsma AA, et al. Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med. 2011;52(8):1235-9.

139.Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70(3):374-83.

140.Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain : a journal of neurology. 2013;136(Pt 1):28-42.

141.Hughes JL, Beech JS, Jones PS, Wang D, Menon DK, Baron JC. Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat. Neuroimage. 2010;49(1):19-31.

142.Tancredi V, D’Arcangelo G, Grassi F, Tarroni P, Palmieri G, Santoni A, et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neuroscience letters. 1992;146(2):176-8.

143.Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, et al. Control of synaptic strength by glial TNFalpha. Science. 2002;295(5563):2282-5.

144.Pickering M, Cumiskey D, O’Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol. 2005;90(5):663-70.

145.Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature. 2006;440(7087):1054-9.

146.Bains JS, Oliet SH. Glia: they make your memories stick! Trends Neurosci. 2007;30(8):417-24.

147.Tobinick E. Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res. 2007;4(5):550-2.

148.Wang Y. P4-266: Modification of synaptic plasticity by TNF and sphingomyelinase: Implications for cognitive impairment in Alzheimer’s disease. Alzheimer’s and Dementia. 2008;4(4 Supplement):T749.

149.Nygard M, Lundkvist GB, Hill RH, Kristensson K. Rapid nitric oxide-dependent effects of tumor necrosis factor-alpha on suprachiasmatic nuclei neuronal activity. Neuroreport. 2009;20(2):213-7.

150.Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, et al. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem. 2009;109(5):1237-49.

151.Beattie MS, Ferguson AR, Bresnahan JC. AMPA-receptor trafficking and injury-induced cell death. Eur J Neurosci. 2010;32(2):290-7.

152.Cavanagh C, Colby-Milley J, Farso M, Krantic S, Quirion R. Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer’s disease: focus on TNF-alpha and IL-1Beta. Future Neurology. 2011;6(6):757-69.

153.Rossi D, Martorana F, Brambilla L. Implications of gliotransmission for the pharmacotherapy of CNS disorders. CNS Drugs. 2011;25(8):641-58.

154.Santello M, Volterra A. TNFalpha in synaptic function: switching gears. Trends Neurosci. 2012;35(10):638-47.

155.Brambilla L, Martorana F, Rossi D. Astrocyte signaling and neurodegeneration: New insights into CNS disorders. Prion. 2013;7(1):28-36.

156.Faingold CL. Chapter 7: Network Control Mechanisms: Cellular Inputs, Neuroactive Substances, and Synaptic Changes. In: Faingold CL, Blumenfeld H, editors. Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics: Elsevier; 2014.

157.Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Experimental neurology. 1998;151(1):138-42.

158.Lindenlaub T, Teuteberg P, Hartung T, Sommer C. Effects of neutralizing antibodies to TNF-alpha on pain-related behavior and nerve regeneration in mice with chronic constriction injury. Brain research. 2000;866(1-2):15-22.

159.Sommer C, Lindenlaub T, Teuteberg P, Schafers M, Hartung T, Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain research. 2001;913(1):86-9.

160.Ignatowski TA, Covey WC, Knight PR, Severin CM, Nickola TJ, Spengler RN. Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 1999;841(1-2):70-7.

161.Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res. 2000;859(1):113-22.

162.Covey WC, Ignatowski TA, Renauld AE, Knight PR, Nader ND, Spengler RN. Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent pain. Reg Anesth Pain Med. 2002;27(4):357-66.

163.Reynolds JL, Ignatowski TA, Spengler RN. Effect of tumor necrosis factor-alpha on the reciprocal G-protein-induced regulation of norepinephrine release by the alpha2-adrenergic receptor. J Neurosci Res. 2005;79(6):779-87.

164.Ignatowski TA, Spengler RN. II. Cytokines in the Brain, B. Cytokines in Brain Physiology: Cytokines in Synaptic Function. In: Phelps C, Korneva E, editors. NeuroImmune Biology, Vol 6: Cytokines and the Brain. Amsterdam, The Netherlands: Elsevier; 2008. p. 111-44.

165.Martuscello RT, Spengler RN, Bonoiu AC, Davidson BA, Helinski J, Ding H, et al. Increasing TNF levels solely in the rat hippocampus produces persistent pain-like symptoms. Pain. 2012;153(9):1871-82.

166.Ignatowski TA, Gerard BA, Bonoiu AC, Mahajan S, Knight PR, Davidson BA, et al., editors. Reduction of tumor necrosis factor (TNF) in the hippocampus alleviates neuropathic pain perception. . Proceedings of the 4th International Congress on Neuropathic Pain Pp 29-35; 2013.

167.Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst. 2001;6(2):67-72.

168.Tobinick EL. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther. 2003;25(8):2279-88.

169.Tobinick EL. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin Ther. 2003;25(4):1211-8.

170.Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly. 2003;133(11-12):170-7.

171.Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin. 2004;20(7):1075-85.

172.Cohen SP, Bogduk N, Dragovich A, Buckenmaier CC, 3rd, Griffith S, Kurihara C, et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology. 2009;110(5):1116-26.

173.Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine. 2012;37(6):439-44.

174.Freeman BJ, Ludbrook GL, Hall S, Cousins M, Mitchell B, Jaros M, et al. Randomized, Double-blind, Placebo-Controlled, Trial of Transforaminal Epidural Etanercept for the Treatment of Symptomatic Lumbar Disc Herniation. Spine. 2013;38(23):1986-94.

175.Kaufman EL, Carl A. Biochemistry of Back Pain. The Open Spine Journal. 2013;5:12-8.

176.Sainoh T, Orita S, Yamauchi K, Suzuki M, Sakuma Y, Kubota G, et al. Intradiscal Administration of Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, Clinically Improves Intractable Discogenic Low Back Pain: A Prospective Randomized Study.  International Society for the Study of the Lumbar Spine 40th Annual Meeting; Scottsdale, Arizona2013.

177.Winkelstein BA, Allen KD, Setton LA. Chapter 19: Intervertebral Disc Herniation: Pathophysiology and Emerging Therapies. In: Shapiro IM, Risbud MV, editors. The Intervertebral Disc. Wien, Austria: Springer-Verlag; 2014.

178.Zanella JM, Burright EN, Hildebrand K, Hobot C, Cox M, Christoferson L, et al. Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model. Spine. 2008;33(3):227-34.

179.Watanabe K, Yabuki S, Sekiguchi M, Kikuchi S, Konno S. Etanercept attenuates pain-related behavior following compression of the dorsal root ganglion in the rat. Eur Spine J. 2011;20(11):1877-84.

180.Coelho SC, Bastos-Pereira AL, Fraga D, Chichorro JG, Zampronio AR. Etanercept reduces thermal and mechanical orofacial hyperalgesia following inflammation and neuropathic injury. European journal of pain. 2014.

181.Clark IA, Ilschner S, MacMicking JD, Cowden WB. TNF and Plasmodium berghei ANKA-induced cerebral malaria. Immunol Lett. 1990;25(1-3):195-8.

182.Clark IA, Rockett KA, Cowden WB. Role of TNF in cerebral malaria. Lancet. 1991;337(8736):302-3.

183.Clark IA, Cowden WB. Roles of TNF in malaria and other parasitic infections. Immunol Ser. 1992;56:365-407.

184.Clark IA, Rockett RA, Cowden WB. TNF in cerebral malaria. Q J Med. 1993;86(3):217-8.

185.Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 2007;18(3-4):335-43.

186.Clark IA. Along a TNF-paved road from dead parasites in red cells to cerebral malaria, and beyond. Parasitology. 2009;136(12):1457-68.

187.Ross SA, Halliday MI, Campbell GC, Byrnes DP, Rowlands BJ. The presence of tumour necrosis factor in CSF and plasma after severe head injury. Br J Neurosurg. 1994;8(4):419-25.

188.Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1994;14(4):615-9.

189.Laws SM, Perneczky R, Wagenpfeil S, Muller U, Forstl H, Martins RN, et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat. 2005;26(1):29-35.

190.Wang Q, Wu J, Rowan MJ, Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci. 2005;22(11):2827-32.

191.Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH, Edwards KL, et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol. 2006;63(8):1165-9.

192.Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci. 2007;27(20):5394-404.

193.Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Camma C, et al. Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer’s disease. Brain Res Rev. 2009;61(2):60-8.

194.Giuliani F, Vernay A, Leuba G, Schenk F. Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism. Brain Res Bull. 2009;80(4-5):302-8.

195.Sarajarvi T, Helisalmi S, Antikainen L, Makinen P, Koivisto AM, Herukka SK, et al. An association study of 21 potential Alzheimer’s disease risk genes in a Finnish population. J Alzheimers Dis. 2010;21(3):763-7.

196.Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, et al. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011;1368:239-47.

197.Shi JQ, Wang BR, Jiang WW, Chen J, Zhu YW, Zhong LL, et al. Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer’s disease. J Am Geriatr Soc. 2011;59(6):1142-4.

198.Butchart J, Holmes C. Systemic and Central Immunity in Alzheimer’s Disease: Therapeutic Implications. CNS Neuroscience & Therapeutics. 2012.

199.Maudsley S, Chadwick W. Progressive and unconventional pharmacotherapeutic approaches to Alzheimer’s disease therapy. Curr Alzheimer Res. 2012;9(1):1-4.

200.Williams M, Coyle JT. Chapter 7: Historical perspectives on the discovery and development of drugs to treat neurological disorders. In: Barrett JE, Coyle JT, Williams M, editors. Translational Neuroscience: Applications in Psychiatry, Neurology, and Neurodevelopmental Disorders. Cambridge, England: Cambridge University Press; 2012. p. 129-48.

201.Clark IA, Vissel B. Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochem Pharmacol. 2013;86(7):862-71.

202.McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neuroscience and biobehavioral reviews. 2009;33(3):355-66.

203.Trollor JN, Smith E, Baune BT, Kochan NA, Campbell L, Samaras K, et al. Systemic inflammation is associated with MCI and its subtypes: the Sydney Memory and Aging Study. Dementia and geriatric cognitive disorders. 2010;30(6):569-78.

204.Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Koerner H, et al. TNF-alpha and its receptors modulate complex behaviours and neurotrophins in transgenic mice. Psychoneuroendocrinology. 2013;38(12):3102-14.

205.Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape journal of medicine. 2008;10(6):135.

206.Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration. 2010;80(3):212-9.

207.Chen YM, Chen HH, Lan JL, Chen DY. Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint, bone, spine : revue du rhumatisme. 2010;77(4):366-7.

208.Bassi E, De Filippi C. Beneficial neurological effects observed in a patient with psoriasis treated with etanercept. Am J Clin Dermatol. 2010;11 Suppl 1:44-5.

209.Butterworth RF. Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology. 2011;53(4):1372-6.

210.D’Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci. 2009;29(7):2089-102.

211.Bemeur C, Qu H, Desjardins P, Butterworth RF. IL-1 or TNF receptor gene deletion delays onset of encephalopathy and attenuates brain edema in experimental acute liver failure. Neurochemistry international. 2010;56(2):213-5.

212.Jiang W, Desjardins P, Butterworth RF. Direct evidence for central proinflammatory mechanisms in rats with experimental acute liver failure: protective effect of hypothermia. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2009;29(5):944-52.

213.Jiang W, Desjardins P, Butterworth RF. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline. J Neurochem. 2009;109(2):485-93.

214.Chastre A, Belanger M, Beauchesne E, Nguyen BN, Desjardins P, Butterworth RF. Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications. PloS one. 2012;7(11):e49670.

215.Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, 3rd, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988;6(2):344-50.

216.Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. Journal of the National Cancer Institute. 1988;80(13):1039-44.

217.Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. MedGenMed. 2006;8(2):25.

218.Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Journal of neuroinflammation. 2008;5:2.

219.Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC neurology. 2008;8:27.

220.Kato K, Kikuchi S, Shubayev VI, Myers RR. Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience. 2009;160(2):492-500.

221.Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O. Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol. 2011;48(2):135-42.

222.Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. Journal of clinical immunology. 1999;19(4):223-30.

223.Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1200-5.

224.Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging. 2010;31(11):1877-84.

225.Chou RC, Kane MA, Ghimire S, Gautam S. Tumor Necrosis Factor Inhibition Reduces the Incidence of Alzheimer’s Disease in Rheumatoid Arthritis Patients.  Amercian College of Rheumatology Annual Meeting, presentation 6402010.

226.Walsh N. ACR: Anti-TNF Drugs May Protect Against Alzheimer’s. Medpage Today. 2010 November 9, 2010.

227.Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, et al. Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. Journal of neuroinflammation. 2012;9:99.

228.Belarbi K, Jopson T, Tweedie D, Arellano C, Luo W, Greig NH, et al. TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. Journal of neuroinflammation. 2012;9:23.

229.McNaull BB, Todd S, McGuinness B, Passmore AP. Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. Gerontology. 2010;56(1):3-14.

230.Neurex. Meeting on the roles of TNF in brain dysfunction and disease. Basel, Switzerland2012.

231.Howick J, Chalmers I, Glasziou P, Greenhaigh T, Heneghan C, Liberati A, et al. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence.2011 March 20, 2014. Available from: http://www.cebm.net/index.aspx?o=5653.

232.Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ. 2006;333(7581):1267-9.

233.Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349-51.

234.Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327(7429):1459-61.

235.Sheridan C. J&J’s billion dollar punt on anti-amyloid antibody. Nat Biotechnol. 2009;27(8):679-81.

236.Guidance for off-label use of drugs. Lancet Neurol. 2008;7(4):285.

237.Committee on Drugs Policy Statement: Off-Label Use of Drugs in Children. Pediatrics. 2014;133(DOI:10.1542/peds.2013-4060):563.

238.American Psychiatric Association. The principles of medical ethics : with annotations especially applicable to psychiatry. 2001 ed. Washington, D.C.: American Psychiatric Association; 2001. 46 p. p.

239.Beck JM, Azari ED. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J. 1998;53(1):71-104.

240.Demonaco HJ, Ali A, Hippel E. The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy. 2006;26(3):323-32.

241.Ghaemi SN, Goodwin FK. The ethics of clinical innovation in psychopharmacology: Challenging traditional bioethics. Philos Ethics Humanit Med. 2007;2:26.

242.Horrobin DF. Effective clinical innovation: an ethical imperative. Lancet. 2002;359(9320):1857-8.

243.Vox F, Capron AM, Kraus MF, Alexander GC, Kirschner KL. Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use. PM R. 2013;5(10):882-9.

244.Dacks PA, Bennett DA, Fillit HM. Evidence needs to be translated, whether or not it is complete. JAMA Neurol. 2014;71(2):137-8.

245.Riggs JE. Tissue-type plasminogen activator should not be used in acute ischemic stroke. Arch Neurol. 1996;53(12):1306-8.

246.Zivin JA, Simmons JG. tPA for Stroke: The Story of a Controversial Drug: Oxford University Press; 2010.

247.Wolinsky H. Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’. EMBO Rep. 2008;9(5):416-8.

248.Grant GJ, Grant AH, Lockwood CJ. Simpson, Semmelweis, and transformational change. Obstet Gynecol. 2005;106(2):384-7.

249.Kuhn TS. The structure of scientific revolutions. Chicago: University of Chicago Press; 1962. xv, 172 p. p.

250.Kuhn TS, Conant J, Haugeland J. The road since Structure : philosophical essays, 1970-1993, with an autobiographical interview. Chicago: University of Chicago Press; 2000. viii, 335 p. p.

251.Bauer HH. Dogmatism in science and medicine : how dominant theories monopolize research and stifle the search for truth. Jefferson, N.C.: McFarland & Co., Inc., Publishers; 2012. vii, 293 p. p.

252.Oka T, Wakugawa Y, Hosoi M, Oka K, Hori T. Intracerebroventricular injection of tumor necrosis factor-alpha induces thermal hyperalgesia in rats. Neuroimmunomodulation. 1996;3(2-3):135-40.